The following is a summary of “Prognostic role of interim PET-CT demonstrating partial metabolic response in diffuse large ...

Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

I find strength and hope in the daffodils I grow, helping me face chronic lymphocytic leukemia with renewed determination.

Pierluigi Porcu, MD, speaks to the considerations clinicians need to account for to balance cost, patient experience, and outcomes for those with chronic lymphocytic leukemia (CLL).

The tool analyzes results from standard tests of organ function, tumor burden, and inflammation to predict whether lymphoma patients will respond to treatment.